Malignant Neoplasm of Colon Clinical Trial
Official title:
Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis
Undetected bowel perforation is a rare but dangerous complication of laparoscopic surgery. If the injury is not detected and treated at the time of the surgical procedure, the patient can suffer severe complications, including septic shock and eventually death. The investigator's goal is to test a novel device that can detect bowel gas leakage from perforation and alert the surgeon during the operation by evaluating the gases present in the insufflated abdomen during surgery. This study will determine the ability of the device to be attached to a standard trocar during the operation and periodically draw small samples or aliquots of gas from the abdomen to evaluate the gas and accurately detect gaseous content from the bowel. Before the device can be used to detect bowel perforations, the investigators must first ensure that it can accurately detect bowel gas in an insufflated abdomen.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | April 30, 2025 |
Est. primary completion date | March 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female = 18 years of age. - Documentation of a required elective right laparoscopic hemicolectomy with intracorporeal anastomosis - Subject signed inform consent Exclusion Criteria: - Less than 18 years old - Pregnant or breastfeeding patients - Patients undergoing emergency laparotomy for perforated right colon or trauma - Patients with Intraabdominal abscess, peritonitis, or enteric fistula - Patients who are on peritoneal dialysis - Subjects do not speak English |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University | Sentire Medical Systems |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Methane (CH4) gas | Methane (CH4) gas measured in ppm or mg/L (parts per million or milligrams per liter (mg/L) at 8-time points | during surgery(from start of laparoscopy to the end of surgical procedure) | |
Primary | Hydrogen (H2) gas | Hydrogen (H2) gas measured in ppm or mg/L (parts per million or milligrams per liter (mg/L) at 8-time points | during surgery(from start of laparoscopy to the end of surgical procedure) | |
Secondary | Response time of the Perf-AlertTM device. | The response time of the Perf-AlertTM device measured in seconds from obtaining the sample (from opening the valve to obtain sample) to first detecting a gas presence at the device electronic sensors | during surgery(from start of laparoscopy to the end of surgical procedure) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
Recruiting |
NCT04534075 -
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
|
Phase 3 | |
Completed |
NCT04975256 -
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
|
Phase 1 |